Antiviral immunotherapy represents a cutting-edge approach to enhancing the body's immune response against viral infections. By leveraging agents that stimulate or modulate the immune system, this therapy aims to target and eliminate viruses more effectively than traditional treatments. Among the promising strategies in this field are:
Monoclonal Antibodies: Engineered molecules that mimic the immune system's ability to combat harmful pathogens, specifically binding to viral particles to neutralize them.
Immune Checkpoint Inhibitors: Drugs that unblock the immune system, enabling it to attack virus-infected cells by inhibiting specific proteins that restrict immune responses.
Cytokine Therapy: Utilizing cytokines, such as interferons, to boost the immune response against viruses by modulating the behaviour of immune cells.
Adoptive Cell Transfer: Extracting, modifying, or expanding patient-derived immune cells in the lab before reintroducing them to enhance antiviral activity.
Therapeutic Vaccines: Developing vaccines not just for prevention, but also for treating existing infections by stimulating a targeted immune response.
Trained immunity: Enhancing broad-spectrum innate immune defence mechanism, as induced by beta-glucan or BCG vaccination, against viral infection.
These therapies may offer particularly promising avenues for chronic viral infections like HIV, hepatitis B, and herpes, where traditional antiviral drugs may fall short or resistance is an issue.
This Research Topic aims to consolidate the latest advancements and therapeutic potentials of antiviral immunotherapy. We seek to gather high-quality research articles and reviews that explore innovative strategies and translational progress in this rapidly evolving field.
By gathering a diverse array of research, this collection aims to provide a valuable resource for scientists, clinicians, and policymakers involved in the fight against viral infections. We seek to facilitate the exchange of knowledge, inspire innovative research, and ultimately contribute to the better management and potential eradication of viral diseases.
The Topic Editors encourage submissions on, but not limited to, research themes such as monoclonal antibodies, immune checkpoint inhibitors, cytokine therapy, T Cell response, vaccines, and trained immunity. We invite researchers to submit their latest findings, original research, and reviews (full list of articles accepted by Frontiers in Virology is listed here: https://www.frontiersin.org/journals/virology/for-authors/article-types) to contribute to a comprehensive understanding of the potential and future direction of antiviral immunotherapy.
Keywords:
neutralizing antibody, monoclonal antibody, antiviral, virus infection, vaccine, immunity, cytokine
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Antiviral immunotherapy represents a cutting-edge approach to enhancing the body's immune response against viral infections. By leveraging agents that stimulate or modulate the immune system, this therapy aims to target and eliminate viruses more effectively than traditional treatments. Among the promising strategies in this field are:
Monoclonal Antibodies: Engineered molecules that mimic the immune system's ability to combat harmful pathogens, specifically binding to viral particles to neutralize them.
Immune Checkpoint Inhibitors: Drugs that unblock the immune system, enabling it to attack virus-infected cells by inhibiting specific proteins that restrict immune responses.
Cytokine Therapy: Utilizing cytokines, such as interferons, to boost the immune response against viruses by modulating the behaviour of immune cells.
Adoptive Cell Transfer: Extracting, modifying, or expanding patient-derived immune cells in the lab before reintroducing them to enhance antiviral activity.
Therapeutic Vaccines: Developing vaccines not just for prevention, but also for treating existing infections by stimulating a targeted immune response.
Trained immunity: Enhancing broad-spectrum innate immune defence mechanism, as induced by beta-glucan or BCG vaccination, against viral infection.
These therapies may offer particularly promising avenues for chronic viral infections like HIV, hepatitis B, and herpes, where traditional antiviral drugs may fall short or resistance is an issue.
This Research Topic aims to consolidate the latest advancements and therapeutic potentials of antiviral immunotherapy. We seek to gather high-quality research articles and reviews that explore innovative strategies and translational progress in this rapidly evolving field.
By gathering a diverse array of research, this collection aims to provide a valuable resource for scientists, clinicians, and policymakers involved in the fight against viral infections. We seek to facilitate the exchange of knowledge, inspire innovative research, and ultimately contribute to the better management and potential eradication of viral diseases.
The Topic Editors encourage submissions on, but not limited to, research themes such as monoclonal antibodies, immune checkpoint inhibitors, cytokine therapy, T Cell response, vaccines, and trained immunity. We invite researchers to submit their latest findings, original research, and reviews (full list of articles accepted by Frontiers in Virology is listed here: https://www.frontiersin.org/journals/virology/for-authors/article-types) to contribute to a comprehensive understanding of the potential and future direction of antiviral immunotherapy.
Keywords:
neutralizing antibody, monoclonal antibody, antiviral, virus infection, vaccine, immunity, cytokine
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.